biomarker

It's long.

It's the Low-Dose Carbon Monoxide Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease.

It is also known as the Locomote PD Study.

So it's a phase 2A multicenter, randomized, double-blind, placebo-controlled study.

And that's the self-responsibility because that's how we learn and grow, whether it's relationships or health or work or performance, it's a growing growth process.

Now, you talk about looking at biomarkers as KPIs instead of outsourcing health to just an annual physical.

You know, I'm the president of HeartMath, so that's always interested running a company.

But you're looking at the body as a company and these KPIs, which for those who don't know what it means, it's key performance indicators.

Well, at least that's a biomarker that people can do something about.

Right.

But there are so many biomarkers that people go, what am I supposed to do? It's take a pill of vitamin.

But we find that with the HRV market these days.

There is a group in Sweden, STHML, which is working on a Stockholm test, which is a new kind of biomarker.

We are working with a group on skin strips, and we are talking about the hair samples, and we are talking about the saliva and in the urine, certain exosomes and all those things.

So next few years, you're going to have it less and less invasive, more and more optional testings for predicting the risk of prostate cancer, but Biomarkers don't diagnose prostate cancer.

Biomarkers are the trigger and we have to play it very delicately.

That's where the shared decision making comes that we have to not just make them very anxious.

get them in there, talk about it, individualize the risk, and then take it to the next level.